Introduction
============

Diabetes mellitus is characterized by hyperglycemia caused by the impairment of insulin secretion, insulin resistance (IR), or both ([@B49]; [@B44]). Excessive caloric intake (due to unhealthy lifestyle) increases the risk of development of type 2 diabetes mellitus (T2DM) ([@B28]). High-fat diet (HFD) intake results in progressive lipid accumulation in liver and muscles that conducting to activation of inflammatory cytokines and IR ([@B10]; [@B28]). In T2DM, β-cell failure (a loss of insulin-producing β-cells) results from a multifactorial process initiated by IR, often in the setting of obesity ([@B47]; [@B3]). The consequence of obesity is characterized by IR, hyperglycemia, atherosclerosis, dyslipidemia, and hypertension. As reported, IR in T2DM and metabolic stress (mainly hyperglycemia and hyperlipidemia) acts as major risk factor for diabetic diseases ([@B5]). These risk factors referred to as metabolic syndrome ([@B13]). Metabolic syndrome is known to be associated with a dysregulation of catalytic activities or expression levels of the metabolic enzymes that play a pivotal role in synthesis and/or consumption of glucose, lipid, and proteins ([@B46]).

Diabetic nephropathy (DN) is the most common complication of patients with diabetes. In addition, DN causes progressive renal fibrosis that finally results in end-stage renal disease (ESRD) ([@B24]; [@B32]; [@B27]; [@B19]). Clinical studies find that glomerular basement membrane thickening, extracellular matrix accumulation, glomerular sclerosis, renal tubular atrophy, and renal interstitial fibrosis are pathological characteristics of DN ([@B16]; [@B23]). Many factors contribute to the development of DN such as oxidative stress, chemokines, and inflammation ([@B15]; [@B9]; [@B7]). Studies show that the DN pathological process is irreversible and resistant to clinical therapy ([@B27]). Therefore, it is necessary to identify novel therapeutic drugs to delay the progression of DN.

Microalbuminuria and hyperfiltration in the glomerulus of diabetic kidneys are early features of DN ([@B18]; [@B34]; [@B12]). Glomerular vascular endothelial cells (GVECs) are considered to be critical in maintaining the glomerular filtration barrier ([@B39]; [@B38]; [@B18]). Injury to GVECs may lead to filtration of albumin and renal fibrosis ([@B27]). Recent studies indicate that the endothelial-to-mesenchymal transition (EMT) is a potential source of activated fibroblasts that finally result in renal fibrosis ([@B33]; [@B61]; [@B12]).

Hyperglycemia can induce proinflammatory factors and activate the profibrotic EMT of GVECs in kidneys ([@B33]; [@B57]). Once the EMT is activated, endothelial cells down-regulate the expression of endothelial phenotype-specific markers, such as CD31 and VE-cadherin, while mesenchymal feature-specific markers, such as α-smooth muscle actin (α-SMA) and vimentin, are up-regulated ([@B11]; [@B40]; [@B57]). Consequently, the EMT of these cells leads to activated fibroblasts and enhances the pathological process of renal fibrosis.

Recent data have demonstrated that the transforming growth factor (TGF)-β1/Smad pathway is crucial in the EMT ([@B51]; [@B52]). High glucose (HG) could increase the protein level of TGF-β1, which is a strong stimulus of the EMT in GVECs ([@B25]; [@B60]). Losartan is a classic selective angiotensin II receptor antagonist ([@B42]). The antifibrotic effect of losartan has been elucidated in numerous fibrotic processes ([@B58]; [@B48]; [@B21]; [@B37]). Furthermore, losartan can significantly blunt the TGF-β1/Smad signaling pathway in many different tissues ([@B6]; [@B50]). In this study, we elucidated whether losartan could alleviate renal fibrosis under hyperglycemia in glomeruli through inhibition of the EMT and examined the potential molecular mechanisms.

Materials and Methods {#s1}
=====================

Mice Model and Related Protocols
--------------------------------

All experimental procedures involving animals were approved by the Ethics Committee of College of Life Science and Technology at Huazhong University of Science and Technology. C57BL/6J mice (male, 6--8 weeks) were purchased from Center for Medical Experimental Animals of Wuhan University (Wuhan, China). All mice were maintained in cages (4--6 mice/cage) under a standard light/dark cycle (12:12/h). Male C57BL/6J mice were fed with HFD (60% fat, 20% protein, and 20% carbohydrate as percentages of total kcal) to create a model for hyperglycemia. Briefly, C57BL/6J mice were divided into to a standard diet (STD) group or a HFD group randomly for 30 weeks and then administrated either with losartan or a placebo for an additional 6 weeks. Blood glucose levels were measured with a glucometer (SANNUO, Changsha, China). Mice were divided into three groups randomly: STD control group (*n* = 12); (2) HFD group (diabetic group, *n* = 12); (3) HFD + losartan group (losartan-treated diabetic group, *n* = 12), mice were treated with oral losartan (20 mg/kg/day) in distilled water. Mice in STD and HFD groups were administered y with an equal volume of distilled water, respectively ([@B13]).

Cell Culture and Treatments
---------------------------

Human renal glomerular endothelial cells (GEnCs) were purchased from Sciencell (Carlsbad, CA, United States) and maintained in endothelial cell medium (ECM) supplemented with 10% (volume/volume) fetal bovine serum (Gibico Life Technologies, MD, United States) and 1% endothelial cell growth supplement in a humidified water jacket incubator (Thermo Fisher Scientific, MA, United States) with 5% CO~2~ at 37°C. For losartan related *in vitro* experiments, GEnCs were divided into three groups: (1) NG group (negative control group, [L]{.smallcaps}-glucose), (2) HG group (high [D]{.smallcaps}-glucose group, 30 mmol/L), (3) HG + Los group (high glucose + losartan). For cells losartan treatment, a dose of 20 μM was used. After exposure to glucose for 48 h, cells were harvested for cell lysates preparation and subject to further analysis.

Immunohistochemistry Staining
-----------------------------

In brief, the mice were anesthetized with an intraperitoneal injection of sodium pentobarbital (50 mg/kg). Kidneys were harvested and then fixed overnight in 4% paraformaldehyde (PFA), embedded in paraffin, and sectioned (4.5 μm). Embedded sections were deparaffinized, dehydrated, and rehydrated after being sectioned. After microwave antigen retrieval, endogenous peroxidase blocking at room temperature for 15 mins in dark and normal goat serum blocking in equilibration buffer at room temperature (50 μl/section), sections were subject to immunohistochemical analysis using a polyclonal antibody against CD31, CD68, Mcp1, α-SMA. 3, 30-diaminobenzidine (DAB) was used as a chromogenic substrate, and the sections were counterstained with hematoxylin. Images were photographed with an inverted Nikon Eclipse Ti microscope (Nikon, Tokyo, Japan). Images were further analyzed with the Image-Pro Plus version 6.0 software (Media Cybernetics Inc., MD, United States). For Masson staining, briefly, kidney samples were fixed, sectioned, deparaffinized, stained with Masson composite staining solution, washed with 0.2% acetic acid solution, 5% phosphotungstic acid solution, 0.2% acetic acid solution. After stained with bright green staining solution, washed twice with 0.2% acetic acid solution, dehydrated in absolute alcohol, put in xylene for transparency, and finally sealed with neutral gum for further analysis ([@B26]; [@B54],[@B55]).

Isolation of Mouse Renal Glomeruli Endothelial Cells (MRGECs)
-------------------------------------------------------------

Mice were anesthetized with an intraperitoneal injection of sodium pentobarbital (50 mg/kg). Kidneys were decapsulated and then cut the cortex away from the medulla, chop the cortex into 1--2 mm^2^ pieces. Press this preparation through a sieve of mesh size 250 μm, into a sterile Petri dish on ice, using a 5-mL syringe barrel. This results in the separation of glomeruli from renal tubules, interstitium, and vasculature. Transfer the glomerular-enriched filtrate from the Petri dish into sterile 50 mL falcon tubes on ice. Further pressed paste-like preparation gently through a 105-μm sieve and a second 75-μm filter, washed extensively with PBS. Retained glomeruli were retrieved into 5 mL PBS, washed another three times with PBS and interval centrifugation (2000 r/min, 5 min). Resuspend enriched glomeruli in collagenase solution and incubate at 37°C for 20 mins, collect pellets after centrifugation, and further transferred to gelatin-coated cell culture flask. After 2 weeks of culture, adhered cells were subject to Mini MACS magenetic cells (CD34^+^) separation for MRGECs according the manufacturers instruction.

Pathological Analysis for Glomerular Volume (GV)
------------------------------------------------

In brief, the mean glomerular volume was calculated from the measured GA (glomerular area) as follows: GV = (GA)3/2 × β/d, where β is a dimensionless shape coefficient (β = 1.38 for spheres), and *d* is a size distribution coefficient (*d* = 1.01). GA was defined as the area described by the outer capillary loops of the tuft using a computer imaging analyzer (Image J), *d* was used to adjust for variations in glomerular size ([@B4]; [@B22]).

Real-Time Quantitative PCR
--------------------------

In brief, total RNA was isolated from cells using Trizol reagent (TaKaRa, Dalian, China) and then subject to cDNA synthesis with M-MLV reverse transcriptase (Promega, WI, United States). DNase I (Promega, WI, United States) was used to remove genomic DNA contamination before reverse transcription. Quantitative PCR analysis was carried out using the FastStart Universal SYBR Green Master (Roche, Basel, Switzerland) and a 7900 HT Fast Real-Time PCR System (ABI, IL, United States) ([@B59]).

Western Blotting
----------------

Glomerular endothelial cells (GEnCs) lysates were prepared using Western-IP lysis buffer (Beyotime, Beijing, China) supplemented with proteinase inhibitor cocktail (Roche, Basel, Switzerland). Total protein extracts were subjected to targeting proteins separating, transferred to a PVDF membrane, and blotted with antibodies against targeting proteins (collagen I, collagen III, fibronectin, CD31, α-SMA, VE-cadherin, vimentin, NOX-4, TGF-β1, p-Smad2, t-Smad2, p-Smad3, t-Smad3, GAPDH). The secondary antibody was a goat HRP-conjugated secondary antibody (1:20,000 dilution). The images were captured using a ChemiDoc XRS (Bio-Rad Laboratories, CA, United States) with the SuperSignal West Pico Chemiluminescent Substrate (Pierce Chemical Co., IL, United States) and further analyzed with Gel-Pro analyzer ([@B56]).

Statistical Analysis
--------------------

We have repeated all experiments at least three times. The data were presented as mean ± SD. Statistical analysis was performed using the Student's *t-*test. *P*-value \< 0.05 was considered to be statistically significant.

Results
=======

Effects of Losartan on Kidney Hypertrophy Under High-Fat Diet-induced Hyperglycemia
-----------------------------------------------------------------------------------

It is well established that a long-term HFD induces IR and glucose intolerance. Indeed, HFD-fed mice showed impaired IR and glucose tolerance sensitivity compared to STD-fed mice (Figures [1A,B](#F1){ref-type="fig"}). These results indicate that hyperglycemia model was successfully induced by HFD.

![Long-term HFD induces insulin resistance and glucose tolerance. **(A)** Insulin resistance assay was performed on mice after 30 weeks of a HFD (*n* = 12/group). **(B)** Glucose tolerance assay was performed on mice after 30 weeks of a HFD (*n* = 6 for each group). Data are shown as mean ± SD. ^∗∗^*P* \< 0.01.](fphar-09-01213-g001){#F1}

To study the role of losartan in glucose metabolism and obesity, we first determined the effect of losartan on body weight. Our data showed that the body weights of mice from the HFD and HFD + losartan groups were increased significantly compared with the STD group. No statistical change was found between the HFD and losartan-treated HFD groups (Figure [2A](#F2){ref-type="fig"}).

![Effects of losartan on metabolic parameters in diabetic mice. **(A)** Effect of losartan on body weight (BW). **(B)** Effect of losartan on kidney weight/body weight (KW/BW). **(C)** Fasting glucose evaluation of mice from STD group, HFD group, and HFD + losartan group. **(D)** Microalbuminuria measurement of mice from STD group, HFD group and HFD + losartan group, *n* = 12/group. Three independent experiments were performed. Data are shown as mean ± SD. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01.](fphar-09-01213-g002){#F2}

Hyperglycemia was successfully induced by the HFD (60% fat, 20% protein, and 20% carbohydrate as percentages of total kcal; SaiNuoBio, Beijing, China) for up to 30 weeks (Figure [2C](#F2){ref-type="fig"}). Furthermore, microalbuminuria (a key functional parameter in DN) was significantly increased in HFD compared with STD mice, and losartan administration mediated a partial recovery (Figure [2D](#F2){ref-type="fig"}). Glomerular hypertrophy was generally evaluated using the KW/BW ratio. Our data showed that KW/BW ratio of HFD mice was significantly greater than STD mice, while KW/BW was much reduced in the HFD + losartan group (Figure [2B](#F2){ref-type="fig"}). These data suggest that losartan effectively attenuates kidney hypertrophy.

Losartan Inhibits Hyperglycemia Induced Glomeruli Fibrosis and Inflammation
---------------------------------------------------------------------------

H&E staining analysis showed that HFD mice developed a larger glomerular volume compared with STD mice. However, this change was impaired by administration of losartan (Figures [3A](#F3){ref-type="fig"} first row, [B](#F3){ref-type="fig"}). For assessing fibrosis, Masson trichrome staining indicated the interstitial fibrosis (blue) area. Fibrosis was markedly increased in HFD compared with STD mice, while it was significantly decreased by losartan treatment (Figures [3A](#F3){ref-type="fig"} second row, [C](#F3){ref-type="fig"}). In addition, immunohistochemistry of inflammation markers (CD68 and Mcp1) suggested that the inflammation process was also enhanced in HFD compared with STD mice, while losartan treatment significantly attenuated this change (Figures [3A](#F3){ref-type="fig"} third row, [D,E](#F3){ref-type="fig"}). We got similar results in kidney tissues for Mcp1 protein level using Western blotting assay (Figure [3F](#F3){ref-type="fig"}). Quantification of fibrosis and inflammation is shown in Figures [3C](#F3){ref-type="fig"}--[E](#F3){ref-type="fig"}.

![Pathological analysis of diabetic mice kidney tissues. **(A)** H&E staining, Masson staining, and immunostaining analysis of inflammation markers (CD68, Mcp1) in different groups. **(B)** Glomerular volume analysis of kidney tissues. **(C)** Fibrosis quantification of mice kidneys from different groups. **(D,E)** Inflammation quantification of kidney tissues from different groups, *n* = 12/group. **(F)** Kidney tissue content of MCP-1 analysis. Three independent experiments were performed. Data are shown as mean ± SD. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01.](fphar-09-01213-g003){#F3}

We also carried out real time qPCR and Western blotting analysis to evaluate the fibrosis status of kidneys. The mRNA levels of collagen I, collagen III, and fibronectin were significantly increased in HFD compared with STD mice, and markedly decreased by losartan administration (Figures [4A](#F4){ref-type="fig"}--[C](#F4){ref-type="fig"}). Similarly, the kidneys protein levels of collagen I, collagen III, and fibronectin were significantly increased in HFD compared with STD mice, while they were markedly decreased by losartan (Figure [4D](#F4){ref-type="fig"}). Quantification of collagen I, collagen III, and fibronectin expression is shown in Figures [4E](#F4){ref-type="fig"}--[G](#F4){ref-type="fig"}. These data suggest that losartan functions as a protective reagent against fibrosis and inflammation under hyperglycemia.

![Effect of losartan on fibrosis in kidneys. **(A--C)** The mRNA levels of *collagen I*, *collagen III*, and *fibronectin* in kidneys. **(D)** Western blotting assay of collagen I, collagen III and fibronectin in different groups. **(E--G)** Quantification of collagen I, collagen III, and fibronectin for Western blotting in different groups, GAPDH was used as a loading control. Three independent experiments were performed. Data are shown as mean ± SD. ^∗∗^*P* \< 0.01.](fphar-09-01213-g004){#F4}

Losartan Alleviates the EMT in Glomeruli Under Hyperglycemia
------------------------------------------------------------

The EMT is a process in which endothelial cells lose their endothelial features (CD31 and VE-cadherin) and gain mesenchymal features (vimentin and α-SMA) ([@B42]). To assess the effect of losartan on the EMT in glomeruli under hyperglycemia, immunohistochemistry was performed. The results showed that the protein level of CD31 in glomeruli was markedly reduced, but the protein level of α-SMA was increased significantly in HFD compared with STD mice. Furthermore, these changes were impaired by the administration of losartan (Figures [5A,B](#F5){ref-type="fig"}). Western blotting assays indicated that both CD31 and VE-cadherin were decreased significantly in HFD compared with STD mice, and losartan administration mediated a partial recovery. In contrast, the protein levels of mesenchymal markers (α-SMA and vimentin) were increased in HFD compared with STD mice, while these changes were reduced by losartan administration (Figures [5C,D](#F5){ref-type="fig"}). These data suggest that losartan alleviates the EMT under hyperglycemia.

![Effect of losartan on EndMT in kidneys. **(A,B)** Immunostaining for CD31 and α-SMA. **(C)** Western blotting assay of endothelial cell markers (CD31, VE-cadherin) and fibroblast markers (α-SMA, vimentin) in different groups. **(D)** Quantification of CD31, VE-cadherin, α-SMA, and vimentin for Western blotting assay in different groups, GAPDH was used as a loading control, *n* = 12/group. Three independent experiments were performed. Data are shown as mean ± SD. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01.](fphar-09-01213-g005){#F5}

Effects of Losartan Administration on Oxidative Stress Under Hyperglycemia
--------------------------------------------------------------------------

Glomerular vascular endothelial cells are increasingly considered to have critical functions in maintaining the glomerular filtration barrier ([@B41]; [@B35]). Oxidative stress is a key factor accounting for endothelial dysfunction in diabetic mice. To assess the effects of losartan on oxidative stress under hyperglycemia, oxidative stress-related markers were examined. The malondialdehyde (MDA) level was increased in kidneys of HFD mice, while losartan treatment decreased this level significantly (Figure [6A](#F6){ref-type="fig"}). Antioxidants, such as superoxide dismutase (SOD) and catalase (CAT), were also examined. The results showed that the activities of SOD and CAT were decreased in kidneys of HFD mice, while losartan treatment diminished these changes (Figures [6B,C](#F6){ref-type="fig"}). Immunohistochemistry and Western blotting analyses were carried out to examine the expression of NOX-4. Our data showed that HFD mice had elevated expression of NOX-4 in kidneys compared with STD mice, but losartan treatment markedly reduced NOX-4 expression (Figures [6D,E](#F6){ref-type="fig"}). These data suggest that losartan functions as a protective agent against oxidative stress damage.

![Losartan inhibits oxidative stress damage in kidneys. **(A--C)** The production of lipid peroxidation and related catalyzing enzymes (MDA, SOD, CAT) in all groups. **(D)** Immunohistochemistry analysis of NOX4 in kidneys. **(E,F)** Western blotting assay of NOX4 protein and quantification of NOX4 in different groups. GAPDH was used as a loading control, *n* = 12/group. Three independent experiments were performed. Data are shown as mean ± SD. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01.](fphar-09-01213-g006){#F6}

Losartan Attenuates the TGF-β1/Smad Pathway Under Hyperglycemia
---------------------------------------------------------------

Previous data have shown that the TGF-β1/Smad pathway is pivotal in development of the EMT ([@B45]). Therefore, we also examined the status of the TGF-β1/Smad pathway in glomeruli. Immunohistochemistry of TGF-β1 showed that its expression in HFD mice was markedly elevated compared with STD mice, while treatment with losartan decreased TGF-β1 expression under hyperglycemia stress (Figures [7A,B](#F7){ref-type="fig"}). Real time qPCR results indicated that the mRNA levels of *TGF-β1* and *Atgr1* were increased in HFD compared with STD mice (Figures [7C,D](#F7){ref-type="fig"}). Western blotting analysis data showed that the protein levels of phospho-Smad2/3 in HFD mice were markedly increased compared with STD mice, but the protein levels of phospho-Smad2/3 in losartan-treated mice were markedly reduced (Figure [7E](#F7){ref-type="fig"}). These data indicate that losartan suppresses activation of the TGF-β1/Smad2/3 pathway under hyperglycemia stress.

![Losartan affects TGF-β1/Smad pathway in kidneys. **(A,B)** Immunohistochemistry analysis for TGF-β1. **(C,D)** The mRNA levels of *TGF-β1* and *Agtr1* in kidneys. **(E)** Protein levels analysis of TGF-β1 and phospho-Smad2/3 proteins from different groups. GAPDH was used as a loading control, *n* = 12/group. Three independent experiments were performed. Data are shown as mean ± SD. ^∗∗^*P* \< 0.01.](fphar-09-01213-g007){#F7}

Losartan Suppresses the HG-Induced EMT *in vitro*
-------------------------------------------------

To further evaluate whether losartan could inhibit the HG-induced EMT *in vitro*, we treated GEnCs with losartan and HG. The immunofluorescence assay showed that the expression of α-SMA in GEnCs was significantly elevated in the HG compared with NG group, while this was reversed by treatment with losartan (Figure [8A](#F8){ref-type="fig"}). The mRNA level of CD31 was reduced, but the mRNA level of α-SMA was increased in the HG compared with NG group. In contrast, losartan markedly increased the mRNA level of CD31 and decreased the expression of α-SMA (Figures [8B,C](#F8){ref-type="fig"}). Western blotting analyses indicated that the protein level of CD31 in the HG group was markedly reduced compared with the NG group, while the level of α-SMA in losartan-treated mice was significantly increased (Figure [8D](#F8){ref-type="fig"}). The protein expression of phospho-Smad2/3 was elevated after exposure to HG when compared with the NG group. By contrast, in the HG + losartan group, the level of phospho-Smad2/3 was significantly reduced (Figure [8E](#F8){ref-type="fig"}).

![Effect of losartan on high glucose induced endothelial-to-mesenchymal transition in GEnCs. **(A)** Immunofluorescence analysis of α-SMA (fibroblast marker) in different groups. **(B,C)** The mRNA levels of CD31 and α-SMA induced by high glucose in GEnCs. **(D)** Protein levels analysis of CD31 and α-SMA protein induced by high glucose in GEnCs. **(E)** Protein levels analysis of phospho-Smad2/3 proteins induced by high glucose in GEnCs. GAPDH was used as a loading control. Three independent experiments were performed. Data are shown as mean ± SD. ^∗∗^*P* \< 0.01.](fphar-09-01213-g008){#F8}

Furthermore, we isolated the glomerular endothelial cells from mouse kidneys (MRGECs), and then incubated with high glucose with or without losartan. We got the similar results in isolated primary MRGECs (Figures [9A,B](#F9){ref-type="fig"}). These data indicate that losartan inhibits the EMT progression induced by HG *in vitro*.

![Effect of losartan on high glucose induced endothelial-to-mesenchymal transition in MRGECs. **(A)** Protein levels analysis of CD31 and α-SMA protein induced by high glucose in MRGECs. **(B)** Protein levels analysis of phospho-Smad2/3 proteins induced by high glucose in MRGECs. GAPDH was used as a loading control. Three independent experiments were performed. Data are shown as mean ± SD. ^∗∗^*P* \< 0.01.](fphar-09-01213-g009){#F9}

Discussion
==========

High-fat diet -fed mice resembled metabolic syndrome and induces many features of the metabolic syndrome, including IR, hyperlipidaemia, glucose intolerance, increased body weight, adiposity, and hyperinsulinemia ([@B20]). T2DM and related kidney disorders are increasing in pandemic proportions largely driven by the exponential rise in obesity ([@B31]). An important and growing complication of T2DM is DN ([@B29]).

Previous data confirmed that DN is one of the most serious microvascular complications of diabetes. It has various causes including poor glycemic control, high blood pressure, and high cholesterol (especially hypertriglyceridemia) ([@B2]; [@B53]). Clinical research shows that DN is responsible for almost half of all incident cases of ESRD in the United States and has become a worldwide health problem ([@B30]). In addition, the 5-year survival of ESRD patients is less than 40%. The number of DN patients at end stage is still increasing yearly ([@B30]; [@B8]). Therefore, it is necessary to find the potential pathogenic mechanism(s) and novel therapeutic agents for treating DN.

It is widely accepted that targeting the renin--angiotensin system in DN by angiotensin receptor blockers provides renal protective effects. However, the potential molecular mechanism behind their protective functions is still incompletely understood ([@B36]). In this study, we showed that losartan treatment suppressed microalbuminuria, renal hypertrophy, and the EMT, and finally attenuated renal fibrosis, with no impact on the blood glucose level in a HFD-induced hyperglycemia mouse model. Furthermore, losartan inhibited the EMT both *in vivo* and *in vitro*. Simultaneously, losartan inhibited the TGF-β1/Smad pathway and reduced the generation of reactive oxygen species (ROS).

Recent studies found that renal endothelial cells can transform into a fibroblast phenotype in renal dysfunction and fibrosis ([@B11]; [@B42]). The process of cell phenotype reprogramming is called the EMT ([@B11]). The EMT is widely considered as a novel process related to the pathology of renal fibrosis ([@B11]). Importantly, several studies proposed that the EMT contributed to renal fibrosis of DN ([@B43]). During progression of the EMT, endothelial cells lose endothelial-specific markers such as CD31 and VE-cadherin, while gaining mesenchymal fibroblast-like markers including α-SMA and vimentin ([@B42]). A novel finding of our present study is that losartan administration attenuated the EMT development induced by HG both *in vivo* and *in vitro*.

Decades of research show that the TGF-β1/Smad signaling pathway plays a crucial role in the EMT ([@B50]; [@B45]). Inhibition of TGF-β1/Smad signaling can significantly blunt the HG-induced EMT ([@B62]). In this research, we found that losartan treatment effectively reversed the increased level of TGF-β1 and the phosphorylation of Smad2/3 in DN. Meanwhile, *in vitro* data indicated that the HG-induced activation of TGF-β1/Smad signaling was markedly suppressed by losartan in GVECs.

It's widely accepted that ROS have critical functions in the development of DN ([@B17]). Hyperglycemia can induce oxidative stress, which leads to renal cell apoptosis, causing renal injury and kidney fibrosis ([@B17]). In addition, ROS can increase extracellular matrix protein synthesis in renal cells, followed by the development of DN ([@B1]). MDA is an oxidative stress marker, and increases in CAT and SOD are also considered as markers of oxidative stress ([@B42]). Our results showed that the level of MDA was elevated in the HFD-induced diabetic group, as well as decreased activities of CAT and SOD. However, after losartan treatment, the level of MDA was decreased, and the activities of CAT and SOD were significantly increased. Furthermore, losartan attenuated the renal expression of NOX4, which was induced by hyperglycemia. These data demonstrate that losartan alleviates renal damage and suppresses DN development via inhibition of oxidative stress damage.

Conclusion
==========

Losartan is a U.S. Food and Drug Administration-approved angiotensin receptor blocker that is used widely to treat hypertension and aortic aneurysm patients ([@B14]). We demonstrated that losartan alleviated renal damage in DN and blunted the EMT in glomeruli. Together, these data suggest that losartan may be developed as a potential agent for the clinical treatment of DN.
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